Leading Biotechnology Companies in the USA and Canada
In 2025, biotechnology is advancing fast, fueled by gene editing, mRNA, and precision medicine. Companies are tackling complex diseases like cancer, neurological, and autoimmune disorders. AI and machine learning are speeding up drug discovery, while regulators adapt to approve breakthrough therapies, making the biotech landscape in the USA and Canada more competitive than ever.
Market Growth
The biotechnology market is expected to grow from USD 1,744.83 billion in 2025 to USD 5,036.46 billion by 2034, at a CAGR of 12.5%, driven by innovation and technological advancements.
Leading Biotech Companies in the USA
1. Amgen Inc.
Products: Amgen's portfolio includes biologic therapies such as Enbrel for autoimmune diseases and Repatha for cholesterol management.
Role & Responsibilities:
Challenges Faced:
Recent Developments:
- Announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.
- Initiated advanced clinical trials for novel therapies targeting rare genetic diseases.
Latest Innovation:
2. Gilead Sciences
Products: Known for antiviral therapies like Biktarvy for HIV treatment and Veklury for COVID-19.
Role & Responsibilities:
- Leads in antiviral research, oncology, and liver diseases.
- Invests in global health initiatives to expand access to essential medicines.
Challenges Faced:
- Expanding its oncology pipeline amidst market competition.
- Managing the lifecycle of blockbuster drugs and addressing pricing concerns.
Recent Developments:
- Initiated a Phase 3 trial for an investigational hepatitis B therapy, aiming to improve cure rates.
- Groundbreaking ceremony for a new manufacturing hub in the Bay Area as part of a $32 billion U.S. investment.
Latest Innovation:
- Exploring gene editing technologies to develop next-generation antiviral treatments.
3. Vertex Pharmaceuticals
Products: Renowned for cystic fibrosis treatments like Trikafta.
Role & Responsibilities:
- Expanding into gene editing and rare disease therapies.
- Collaborating with academic institutions to advance scientific research.
Challenges Faced:
- Diversifying its portfolio beyond cystic fibrosis.
- Navigating regulatory landscapes for new therapies.
Recent Developments:
- Announced key advancements across its kidney disease portfolio.
- Entered into a partnership with CRISPR Therapeutics to develop gene-editing therapies for sickle cell disease.
Latest Innovation:
- Advancements in gene-editing technologies are showing promise in treating genetic disorders.
Leading Biotech Companies in Canada
1. Zymeworks Inc.
Products: Develops multifunctional therapeutics, including bispecific antibodies for cancer treatment.
Role & Responsibilities:
- Focuses on precision medicine and immuno-oncology.
- Engages in strategic collaborations to enhance its research capabilities.
Challenges Faced:
- Advancing its pipeline through clinical trials and securing partnerships.
- Addressing market competition and regulatory approvals.
Recent Developments:
- Announced FDA clearance of Investigational New Drug Application for ZW251, a novel glypican 3-targeted topoisomerase 1 inhibitor antibody-drug conjugate.
- Received NMPA approval in China for Zanidatamab in adults with previously treated, unresectable or metastatic HER2-high expression biliary tract cancer.
Latest Innovation:
- Advancements in bispecific antibody platforms are showing potential in targeting hard-to-treat cancers.
2. Medicago Inc.
Products: Specializes in plant-based vaccines, including its COVID-19 vaccine candidate.
Role & Responsibilities:
- Focuses on developing rapid-response vaccines for infectious diseases.
- Collaborates with global health organizations to enhance vaccine accessibility.
Challenges Faced:
- Scaling up production and meeting regulatory requirements.
- Addressing public perception and acceptance of plant-based vaccines.
Recent Developments:
- Received emergency use authorization for its plant-based influenza vaccine.
- Announced plans to expand its vaccine pipeline to address emerging infectious diseases.
Latest Innovation:
- Exploring plant-based platforms for developing vaccines against emerging infectious diseases.
3. Deep Genomics
Products: Utilizes AI to discover and develop genetic medicines.
Role & Responsibilities:
- Focuses on precision gene therapies for rare genetic disorders.
- Expands its AI platform to decode complex RNA biology.
Challenges Faced:
- Translating AI discoveries into clinical applications.
- Securing funding and partnerships for research and development.
Recent Developments:
- Expanded its AI foundation model platform for decoding RNA biology, introducing the REPRESS model for predicting microRNA binding and mRNA degradation.
- Initiated a Phase 1 trial for its AI-designed gene therapy targeting a rare neurological disorder.
Latest Innovation:
- Advancements in AI-driven gene therapy are enabling the development of treatments for complex genetic diseases.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
